Ya\u015fl\u0131lar\u0131n herpes zoster\u2019e kar\u015f\u0131 a\u015f\u0131lanmas\u0131n\u0131n s\u0131n\u0131rl\u0131 bir koruyucu etkisi var fakat en y\u00fcksek risk gurubunda (ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin bask\u0131lanmaya ba\u015flad\u0131\u011f\u0131 80 ya\u015f \u00fcst\u00fcnde) yok.<\/p>\n <\/span><\/p>\n 60 ya\u015f ve \u00fczeri 1000 hasta \u00fczerinde yap\u0131lan Klinik \u00e7al\u0131\u015fma sonu\u00e7lar\u0131,<\/span> zoster a\u015f\u0131s\u0131n\u0131n (Zostavax\u00b0, Sanofi\u00a0Pasteur\u00a0MSD) sonraki 3 y\u0131l boyunca her y\u0131l yakla\u015f\u0131k olarak bir vakada\u00a0\u00a0\u00a0herpes sonras\u0131 sinir a\u011fr\u0131s\u0131n\u0131\u00a0\u00a0(postherpetic neuralgia) \u00f6nledi\u011fini g\u00f6stermektedir.<\/span><\/p>\n A\u015f\u0131 70 ya\u015f\u0131n \u00fczerindeki hastalarda daha az etkilidir.<\/span><\/p>\n Oysaki ciddi zoster riskinin en y\u00fcksek oldu\u011fu ba\u011f\u0131\u015f\u0131kl\u0131k yetersizli\u011fi olan bireylerde bu canl\u0131 zoster a\u015f\u0131s\u0131 kontrendikedir.<\/span><\/p>\n